Type 2 Diabetes

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

Orforglipron added to titrated insulin glargine reduced HbA1c by up to 2.05% and body weight by up to 6.1% versus placebo, without increasing hypoglycemia risk.

Eugene Wright, Jr., MD, joins the show to discuss the current state of technological integration into diabetes care, from glucose monitors to insulin delivery and beyond.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.

The CONNECT trial found CGM improved A1C and time in range in adults with type 2 diabetes not on insulin.

STEP UP T2D data suggest semaglutide 7.2 mg's superiority to the 2.4 mg dose and placebo for proposed BMI and waist-to-height ratio treatment targets.

An EHR-based machine learning model predicted 10-year type 2 diabetes risk with near-ideal calibration in over 3 million adult patients.

Catch up on major trial results, key FDA decisions, and more.

View the top 6 trials to watch ahead of a star-studded ADA 2026.

The FDA has approved fast-acting inhaled insulin Afrezza for pediatric patients aged 6-18 years with T1D or T2D.

This episode covers the FDA’s recent approval of MannKind’s inhaled insulin Afrezza for patients aged 6-18 years with either T1D or T2D.

This episode covers Abbott’s Libre Duo and Libre Duo 10 Day systems, Eli Lilly’s retatrutide, and the recent Dexcom sensor theft.

Isaacs covers the range of AID devices currently available and approved for T2D, providing suggestions for implementation and continuous glycated hemoglobin monitoring.

Isaacs explains how prediabetes care is shifting toward early intervention, risk stratification, and prevention of cardiometabolic disease, not just progression to diabetes.

Mechanick discusses the importance of dietary interventions in endocrinology and highlights the need for further education and awareness of metabolic function.

Galindo describes how CKM may transform diabetes care by enabling real-time insights, improving DKA prevention, and advancing metabolic understanding.

RCTs show intermittent fasting and calorie restriction yield similar HbA1c and cardiometabolic outcomes in type 2 diabetes, with modest, nonsignificant weight differences.

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

A recent presentation at AACE 2026 highlights the drastically increased risk of mortality, sepsis, diabetic ketoacidosis, and recurrent acute pancreatitis after GLP-1 initiation.

Beck discusses the recently presented results of INHALE-1, in which technosphere insulin failed to prove noninferiority to RAA but had no pulmonary effects.

Results from the largest and longest trial of orforglipron to date have displayed the drug’s efficacy in reducing all-cause cardiovascular death and MACE incidence.

Although the approval does not permit entrance into the market, this decision marks an important step to more universally accessible GLP-1 RAs.

Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.